Table 2 Breast cancer risk associated with polymorphic variants in GPX1, GPX4, SEPP1, SEP15 and SOD2 genes
Polymorphism | Cases, n (%) | Controls, n (%) | OR crude (95%CI) | p | OR adjusteda (95 % CI) | p |
|---|---|---|---|---|---|---|
GPX1 (rs1050450) | ||||||
Pro/Pro | 73 (53.7) | 75 (41.0) | 1 (ref.) | 1 (ref.) | ||
Leu/Leu | 12 (8.8) | 23 (12.6) | 0.54 (0.25–1.16) | 0.112 | 0.61 (0.28–1.34) | 0.215 |
Pro/Leu + Leu/Leu | 63 (46.3) | 108 (59.0) | 0.60 (0.38–0.94) | 0.026 | 0.61 (0.38–0.97) | 0.035 |
GPX4 (rs713041) | ||||||
CC | 44 (32.4) | 65 (35.5) | 1 (ref.) | 1 (ref.) | ||
TT | 26 (19.1) | 28 (15.3) | 1.37 (0.71–2.66) | 0.345 | 1.31 (0.65–2.66) | 0.445 |
CT + TT | 92 (67.6) | 118 (64.5) | 1.15 (0.72–1.85) | 0.556 | 1.12 (0.68–1.85) | 0.644 |
SEPP1 (rs3877899)b | ||||||
Ala/Ala | 81 (60.4) | 122 (66.7) | 1 (ref.) | 1 (ref.) | ||
Thr/Thr | 9 (6.7) | 6 (3.3) | 2.26 (0.77–6.63) | 0.136 | 2.57 (0.86–7.61) | 0.087 |
Ala/Thr + Thr/Thr | 53 (39.6) | 61 (33.3) | 1.31 (0.82–2.08) | 0.255 | 1.38 (0.85–2.23) | 0.192 |
SEP15 (rs5859) | ||||||
GG | 82 (60.3) | 103 (56.3) | 1 (ref.) | 1 (ref.) | ||
AA | 8 (5.9) | 14 (7.7) | 0.72 (0.28–1.80) | 0.479 | 0.72 (0.27–1.91) | 0.512 |
GA + AA | 54 (39.7) | 80 (43.7) | 0.85 (0.54–1.33) | 0.473 | 0.91 (0.57–1.46) | 0.696 |
SOD2 (rs4880) | ||||||
Ala/Ala | 29 (21.3) | 50 (27.3) | 1 (ref.) | 1 (ref.) | ||
Val/Val | 32 (23.5) | 41 (22.4) | 1.34 (0.70–2,59) | 0.371 | 1.54 (0.76–3.14) | 0.227 |
Ala/Val + Val/Val | 107 (78.7) | 133 (72.7) | 1.39 (0.82–2.35) | 0.221 | 1.67 (0.95–2.96) | 0.076 |